New and recently funded Medical Startups
1
Country: USA | Funding: $241M
Cadence offers a clinical intelligent remote patient monitoring platform for chronic care management for older adults. Its AI-powered Proactive Care Engine analyzes data in real time, alerts clinical teams to emerging health risks between visits, and supports patients in receiving medication adjustments and lifestyle guidance. The company's supervised AI agents monitor patient vital signs daily. The platform is integrated into health systems' medical groups, clinical workflows and electronic medical records.
Cadence offers a clinical intelligent remote patient monitoring platform for chronic care management for older adults. Its AI-powered Proactive Care Engine analyzes data in real time, alerts clinical teams to emerging health risks between visits, and supports patients in receiving medication adjustments and lifestyle guidance. The company's supervised AI agents monitor patient vital signs daily. The platform is integrated into health systems' medical groups, clinical workflows and electronic medical records.
2
Country: Romania
Folicle is a hair-growth tracking app that aligns every scalp photo to the previous frame for consistent angle and lighting, so progress is actually comparable over time. Log treatments (minoxidil, finasteride, and more), watch your Hair Score, and export dermatologist-ready PDF timelines for your next appointment. Non-diagnostic — it documents progress, it does not diagnose or prescribe. iOS + Android; join the waitlist at folicle.app.
Folicle is a hair-growth tracking app that aligns every scalp photo to the previous frame for consistent angle and lighting, so progress is actually comparable over time. Log treatments (minoxidil, finasteride, and more), watch your Hair Score, and export dermatologist-ready PDF timelines for your next appointment. Non-diagnostic — it documents progress, it does not diagnose or prescribe. iOS + Android; join the waitlist at folicle.app.
3
Country: USA | Funding: $645.1M
VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions. Its flagship product, VDPHL01, is the first non-hormonal, oral, extended-release treatment for hair regrowth in women and men. It is an immediate-release oral minoxidil that has demonstrated efficacy in clinical trials. It reaches peak concentrations within one hour and is almost completely eliminated from the body within four hours, limiting the time available for hair growth stimulation and has been associated with cardiotoxicity.
VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions. Its flagship product, VDPHL01, is the first non-hormonal, oral, extended-release treatment for hair regrowth in women and men. It is an immediate-release oral minoxidil that has demonstrated efficacy in clinical trials. It reaches peak concentrations within one hour and is almost completely eliminated from the body within four hours, limiting the time available for hair growth stimulation and has been associated with cardiotoxicity.
4
Country: Singapore | Funding: $35.7M
Gero is developing an AI-driven drug discovery platform focused on slowing aging and treating chronic diseases. It creates AI models of aging based on large-scale, real-life longitudinal data, integrating clinical, molecular, omics, and genetic signals with physically based modeling, and identifies targets directly in human health data. These targets are then tested in known disease models. Company's programs considered for preclinical development include oncology and fibrosis.
Gero is developing an AI-driven drug discovery platform focused on slowing aging and treating chronic diseases. It creates AI models of aging based on large-scale, real-life longitudinal data, integrating clinical, molecular, omics, and genetic signals with physically based modeling, and identifies targets directly in human health data. These targets are then tested in known disease models. Company's programs considered for preclinical development include oncology and fibrosis.
5
Country: USA | Funding: $50M
Avaneer Health creates health insurance platform that provides accurate coverage information by directly connecting payers and providers to accurately update coverage data before services are rendered and reimbursement claims are submitted. When updated or new coverage data is available, the solution automatically identifies missing, inconsistent, or incorrect coverage information. If needed, the information is instantly available in the electronic health record. The system uses blockchain and FHIR technologies to ensure secure data exchange between healthcare organizations.
Avaneer Health creates health insurance platform that provides accurate coverage information by directly connecting payers and providers to accurately update coverage data before services are rendered and reimbursement claims are submitted. When updated or new coverage data is available, the solution automatically identifies missing, inconsistent, or incorrect coverage information. If needed, the information is instantly available in the electronic health record. The system uses blockchain and FHIR technologies to ensure secure data exchange between healthcare organizations.
6
Country: Turkey
Salnus is a deep-tech medical AI startup building AI-powered preoperative surgical planning and clinical decision support for orthopedic surgery. Its software-only, implant-agnostic, browser-based platform runs an end-to-end DICOM pipeline covering knee osteoarthritis assessment, patient-specific surgical guides (PSI), and 3D preoperative surgical planning.
Salnus is a deep-tech medical AI startup building AI-powered preoperative surgical planning and clinical decision support for orthopedic surgery. Its software-only, implant-agnostic, browser-based platform runs an end-to-end DICOM pipeline covering knee osteoarthritis assessment, patient-specific surgical guides (PSI), and 3D preoperative surgical planning.
7
Country: USA | Funding: $1.7B
Intellia is a leading genome editing company specializing in the development of proprietary, potentially curative therapeutics using CRISPR/Cas9 technology. Intellia's co-founder Jennifer Daudna, along with Emmanuelle Charpentier, were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. The company's pipeline includes treatments for hereditary angioedema, transthyretin amyloidosis with polyneuropathy and cardiomyopathy, hemophilia, acute myeloid leukemia, and B-cell malignancies.
Intellia is a leading genome editing company specializing in the development of proprietary, potentially curative therapeutics using CRISPR/Cas9 technology. Intellia's co-founder Jennifer Daudna, along with Emmanuelle Charpentier, were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. The company's pipeline includes treatments for hereditary angioedema, transthyretin amyloidosis with polyneuropathy and cardiomyopathy, hemophilia, acute myeloid leukemia, and B-cell malignancies.
8
Country: France | Funding: €1,5M
deepColor specializes in developing and selling high-resolution 3D vascular imaging solutions using photoacoustic tomography.
deepColor specializes in developing and selling high-resolution 3D vascular imaging solutions using photoacoustic tomography.
9
Country: USA
Mendel Biosciences develops innovative technologies in longevity, regenerative medicine, and AI-powered healthcare to combat age-related diseases and extend healthy human lifespan
Mendel Biosciences develops innovative technologies in longevity, regenerative medicine, and AI-powered healthcare to combat age-related diseases and extend healthy human lifespan
10
Country: USA | Funding: $234.5M
City Therapeutics is focused on developing next-generation small interfering RNAs. Its lead candidate, CITY-FXI, is a potential best-in-class RNA interference-based therapeutic that targets a clotting factor. It can help prevent blood clots and serious conditions such as stroke, deep vein thrombosis (DVT), and myocardial infarction. By targeting a key protein called factor XI, CITY-FXI aims to protect patients from thrombosis while reducing the risk of bleeding. Another candidate, CITY-RBP4, is a promising RNA interference-based therapeutic for preventing vision loss in Stargardt disease.
City Therapeutics is focused on developing next-generation small interfering RNAs. Its lead candidate, CITY-FXI, is a potential best-in-class RNA interference-based therapeutic that targets a clotting factor. It can help prevent blood clots and serious conditions such as stroke, deep vein thrombosis (DVT), and myocardial infarction. By targeting a key protein called factor XI, CITY-FXI aims to protect patients from thrombosis while reducing the risk of bleeding. Another candidate, CITY-RBP4, is a promising RNA interference-based therapeutic for preventing vision loss in Stargardt disease.
